Founder & CEO

Curing the Incurable

Chairman & CEO Ryuji Suzuki

Executive Advisor/Founder
Ryuji Suzuki

The immune system plays an important role in protecting our lives. Specifically, the immune cells consider foreign objects (e.g. viruses and bacteria) as enemies and attack them to remove them from our body. However, the immune system can also have unwanted aspects, such as being responsible for autoimmune diseases and allergies.

Since over a quarter of a century, researchers have focused on providing effective treatment and diagnostic methods for most of the diseases involving the immune system (e.g. infectious diseases, cancers, and autoimmune diseases). This has been done by analyzing in detail the complex immune system.

As a result, we released our unique immune diversity analysis platform simultaneously to establishing our company.
We have addressed unresolved medical issues through critical research support at research institutions such as universities and pharmaceutical companies. Additionally, we obtained Clinical research and Clinical trial support through pharmaceutical companies.

To date, we are expanding our spectrum of research in pathogenesis, diagnostics, drug discovery, and treatment. Our mission is "Curing the Incurable".
In the future, we will strive to further strengthen the pipeline of diagnostic and treatment fields.

Specifically, we are focusing on the cancer immunotherapy field. This field is rapidly accelerating both domestic and overseas research and development.
We will continue to take on the challenge in order to provide effective treatments and diagnostic methods.

President & COOO Masuo Ichikawai

President & CEO
Masuo Ichikawa

The immune system is one of the most sophisticated systems in our bodies for the diagnosis and treatment of most diseases. However, the potential of the immune system has not been fully exploited in the field of medicine to date as its mechanism of action has not been completely elucidated. Our company is developing businesses that support and promote unprecedented new medical development (basic research, prevention, diagnosis, and treatment) using the immune system in a wide range of medical applications by integrating accurate and vast information obtained from our proprietary immune diversity analysis technology.

Since its establishment in October 2014, our company has been analyzing for many diseases such as cancer, infectious diseases, and autoimmune diseases, with a particular focus on the detailed analyses of T cell receptors and B cell receptors on the surfaces of T cells and B cells, respectively, which are two major lymphocyte populations. Moreover, our company has established partnerships with a number of academic institutions and biopharmaceutical companies. In the future, we will continue cooperating with research institutions to advance research and development that contribute to human health by disseminating our unique immune diversity analysis technology to the world, with an aim to understand the immune system better and enable the realization of a world of “Curing the Incurable”.